tiprankstipranks
Advertisement
Advertisement

Cannara Biotech Wins TSX Listing and TD Cowen Coverage

Story Highlights
  • Cannara Biotech will graduate from the TSXV to the TSX on March 2, 2026, boosting visibility and liquidity.
  • TD Cowen has initiated research coverage on Cannara, potentially broadening its investor base in the cannabis sector.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cannara Biotech Wins TSX Listing and TD Cowen Coverage

Claim 55% Off TipRanks

Cannara Biotech ( (TSE:LOVE) ) has shared an update.

Cannara Biotech has secured final approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange, with its common shares set to begin trading on the TSX under the symbol LOVE on March 2, 2026, and concurrent delisting from the TSXV. Management frames the uplisting as a key step in enhancing market visibility, liquidity, and access to institutional investors, signaling a maturing capital markets profile for the Québec-based cannabis producer.

The company also disclosed that TD Cowen has initiated equity research coverage as of February 24, 2026, adding third-party analytical attention to the stock. The combination of a senior exchange listing and new analyst coverage is likely to broaden Cannara’s investor base and could improve its standing within the competitive Canadian cannabis sector.

The most recent analyst rating on (TSE:LOVE) stock is a Buy with a C$3.25 price target. To see the full list of analyst forecasts on Cannara Biotech stock, see the TSE:LOVE Stock Forecast page.

Spark’s Take on TSE:LOVE Stock

According to Spark, TipRanks’ AI Analyst, TSE:LOVE is a Neutral.

The score is driven primarily by solid financial performance—healthy margins, steady revenue growth, and improving leverage—offset by weaker/less consistent free cash flow. Technicals are mixed with neutral momentum and slight short-term softness, while valuation appears reasonable based on the P/E.

To see Spark’s full report on TSE:LOVE stock, click here.

More about Cannara Biotech

Cannara Biotech Inc. is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian market. The company operates two mega cultivation and production facilities in Québec totaling over 1.6 million square feet, leveraging low electricity costs to support up to 100,000 kg of annual cannabis output.

Average Trading Volume: 51,558

Technical Sentiment Signal: Buy

Current Market Cap: C$172.4M

See more insights into LOVE stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1